Project Grant F32AI188624

Award Date 5/1/25
Completion Date Not listed
Dollars Obligated $81K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This $616,814 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of microRNAs in regulating airway smooth muscle function and their contribution to the pathogenesis of asthma. The overarching goal is to establish the in vivo impact of specific microRNAs on airway smooth muscle proliferation, hypertrophy, and contractility, and determine their association with...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $672,657 to Mayo Clinic to investigate the role of transmembrane protein 178 (TMEM178) in regulating inflammation and airway hyperresponsiveness in asthma. The key objectives are to: 1) Test the hypothesis that TMEM178-mediated inhibition of calcium responses is disrupted in asthmatic bronchial epithelial cells (BECs); 2)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support Biotherapeutics, Inc.'s development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The $347,608 award will fund preclinical research to characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, as well as determine its translational potential using...
This Project Grant award for $1,076,800 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research to understand the roles of group 2 innate lymphoid cells (ILC2s) in promoting and regulating type 2 immune responses and airway inflammation in asthma. The project aims to define how ILC2s interact with CD4+ T cells to influence the development of immune memory and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $626,956.00 to Thomas Jefferson University for a study on the role of tRNA- and rRNA-derived small non-coding RNAs in acute lung injury (ALI). The researchers aim to leverage a novel sequencing technique to uncover the dysregulation of these "hidden" small non-coding RNAs, particularly tRNA halves and rRNA fragments, in...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $586,250 to the University of Massachusetts Medical School to conduct research on the generation and regulation of TFH13 cells that drive pathogenic IgE in allergic diseases. The key objectives of this 5-year project are to: 1) determine the role of non-conventional antigen presenting cells in promoting TFH13 cell differentiation to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $466,213 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The funding will support research to study the generation and fate of IgE-expressing B cells and plasma cells in mouse models of allergic airway disease, in order to characterize the cellular response leading to IgE production after aeroallergen exposure...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Biotherapeutics, Inc. a $288,986 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to develop a novel immunoregulatory and immunometabolic therapeutic for treating asthma. The key objectives under this SBIR Phase I award are to: Determine the safety profile and pharmacokinetics of the new asthma therapeutic by evaluating oral bioavailability, distribution, and conducting general toxicity studies in rats. Characterize...
This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $2,250,000 in funding to The Children's Hospital Corporation (Boston Children's Hospital) to conduct a randomized, double-blind, placebo-controlled trial on the use of omalizumab (anti-IgE) to prevent asthma progression and severity in high-risk children ages 2-3. The key objectives are to: 1) Determine whether 2 years of omalizumab...
This $544,608 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to determine whether genetic mutations in the ASCL1 transcription factor contribute to the development of organ-specific autoimmunity in humans. The research aims to understand how ASCL1 mutations may disrupt the function and microenvironment of medullary thymic epithelial cells, which play a critical role in central...

RNA REGULATORY CIRCUITS IN ALLERGIC AIRWAY INFLAMMATION - PROJECT SUMMARY/ABSTRACT ASTHMA IS A CHRONIC INFLAMMATORY AIRWAY CONDITION WITH HIGH GLOBAL PREVALENCE CAUSING SIGNIFICANT MORBIDITY AND MORTALITY. ALLERGIC, "TYPE 2" (T2), INFLAMMATION IS THE DEFINING FEATURE OF ASTHMA IN MANY PATIENTS. TYPE 2 T HELPER (TH2) CELLS AND THE AIRWAY EPITHELIUM, ACTING THROUGH THE CANONICAL T2 CYTOKINES IL-4 AND IL-13, HAVE CENTRAL ROLES IN ASTHMA. POLARIZATION OF T CELLS TOWARDS A TH2 PHENOTYPE VIA IL-4 STIMULATION CREATES A POOL OF TH2 CELLS THAT ARE A MAJOR SOURCE OF IL-13 IN THE AIRWAYS. SUSTAINED AIRWAY EPITHELIAL EXPOSURE TO IL-13 CAUSES GOBLET CELL METAPLASIA AND STIMULATES THE SECRETION OF CHEMOKINES THAT RECRUIT INFLAMMATORY CELLS TO THE LUNG. WHEN LEFT UNCHECKED, THESE CHANGES AMPLIFY OVER TIME, INCREASING DISEASE SEVERITY AND PROMOTING EXACERBATIONS THAT CARRY HIGH MORBIDITY AND MORTALITY. THE MECHANISMS THAT CONTROL THE MAGNITUDE AND DURATION OF T2 SIGNALING IN ASTHMA ARE NOT WELL UNDERSTOOD. IN THIS PROPOSAL, WE SEEK TO IDENTIFY RNA REGULATORY CIRCUITS THAT DRIVE PERSISTENT T2 INFLAMMATION IN T CELLS AND THE AIRWAY EPITHELIUM. POST-TRANSCRIPTIONAL REGULATION IS AN IMPORTANT MECHANISM THAT ALLOWS CELLS TO TUNE THE INTENSITY OF INFLAMMATORY RESPONSES. INTERACTIONS BETWEEN 3' UNTRANSLATED REGIONS (UTRS) ON MRNAS AND RNA BINDING PROTEINS (RBPS) ARE KEY TO THIS REGULATORY LEVEL. RNA BINDING PROTEINS INTERACT WITH THE 3' UTRS, DICTATING TRANSCRIPT STABILITY, DEGRADATION, AND LOCALIZATION. THESE CIRCUITS GIVE CELLS DYNAMIC CONTROL OVER THE FLOW OF TRANSCRIPTOMIC INFORMATION INTO CELLULAR ACTIONS. POST-TRANSCRIPTIONAL REGULATION IS UNDERSTUDIED IN ASTHMA AND PRESENTS THE POTENTIAL TO DEFINE NOVEL MEDIATORS OF T2 INFLAMMATION. OUR LAB RECENTLY IDENTIFIED THE STAT6 3' UTR AS A POTENTIALLY IMPORTANT POST-TRANSCRIPTIONAL REGULATORY ELEMENT IN T2 HIGH ASTHMA. SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) IS A CRITICAL MEDIATOR OF T2 GENE EXPRESSION PROGRAMMING, ACTING AS A TRANSCRIPTION FACTOR IN RESPONSE TO IL-4 AND IL-13. THE STAT6 3' UTR HAS MULTIPLE REGIONS WITH PROTEIN OCCUPANCY AND CONTAINS A SNP (RS1059513) THAT IS HIGHLY ASSOCIATED WITH ASTHMA AND ALLERGY, SUGGESTING REGULATORY CONTROL THAT MAY DICTATE SENSITIVITY TO IL-4 AND IL-13. THROUGH HIGH RESOLUTION MAPPING, WE SEEK TO IDENTIFY FUNCTIONAL ELEMENTS ACROSS THE STAT6 3' UTR AND THEIR ROLE IN REGULATING THE T2 SIGNALING INTENSITY IN T CELLS AND THE AIRWAY EPITHELIUM. WE WILL ASSESS HOW THESE FUNCTIONAL ELEMENTS CONTROL GENE EXPRESSION, CYTOKINE SECRETION, AND EPITHELIAL CELL DIFFERENTIATION. WE HAVE ALSO IDENTIFIED CANDIDATE RBP REGULATORS OF T2 INFLAMMATION IN THE AIRWAY EPITHELIUM WHICH INCLUDE IGF2BP3, ZFP36L1, AND ZFP36L2. USING CRISPR ACTIVATION AND INTERFERENCE, WE WILL EVALUATE HOW THESE PROTEINS CONTROL IL-13 MEDIATED GENE EXPRESSION, PATHOLOGIC MUCUS ACCUMULATION, AND AIRWAY EPITHELIAL CELL DIFFERENTIATION. THESE STUDIES WILL ILLUMINATE CLINICALLY RELEVANT POST-TRANSCRIPTIONAL CIRCUITS IN ASTHMA AND NOMINATE NOVEL PATHWAYS FOR POTENTIAL THERAPEUTIC TARGETING. THIS PROJECT WILL BE COMPLETED THROUGH A POSTDOCTORAL FELLOWSHIP AT UCSF AND WILL UTILIZE COMPREHENSIVE INSTITUTIONAL SUPPORT AND RESOURCES TO PREPARE THE APPLICANT FOR AN INDEPENDENT RESEARCH CAREER.

Posted 12/4/24, 12:00 AM